Page last updated: 2024-10-16

adenine and Co-infection

adenine has been researched along with Co-infection in 52 studies

Research Excerpts

ExcerptRelevanceReference
"Coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (E/C/F/TAF) has high efficacy and improved renal and bone safety in multiple phase 3 trials; TAF single agent is being studied in 2 phase 3 trials in patients with chronic hepatitis B."9.22Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B-Coinfected Adults. ( Benson, P; Brinson, C; Brunetta, J; Cheng, A; Crofoot, G; Das, M; Fordyce, M; Gallant, J; Garner, W; McCallister, S; Mills, A; Oka, S, 2016)
"A 48-week PegIFN therapy was added to HBeAg positive-HIV co-infected patients on TDF and emtricitabine, or lamivudine for at least 6 months."9.19Role of a 48-week pegylated interferon therapy in hepatitis B e antigen positive HIV-co-infected patients on cART including tenofovir: EMVIPEG study. ( Barthe, Y; Bouix, C; Cacoub, P; Carrat, F; Lascoux-Combe, C; Lebossé, F; Maynard-Muet, M; Miailhes, P; Piroth, L; Pol, S; Rey, D; Sogni, P; Zoulim, F, 2014)
" Treatment of chronic hepatitis C in patients coinfected with HIV is a complex problem associated with toxicities and drug interactions between HIV antiretrovirals and interferon and ribavirin."7.79Short communication: Interferon/ribavirin treatment for HCV is associated with the development of hypophosphatemia in HIV/hepatitis C virus-coinfected patients. ( Funk, EK; Heytens, L; Kohli, A; Kottilil, S; Kwan, R; Masur, H; Nelson, A; Polis, MA; Shaffer, A; Shivakumar, B; Sneller, M, 2013)
"This study assessed HIV-hepatitis B virus (HBV) coinfection in southern Africa in terms of prevalence, viral characteristics, occult HBV, and the effect of lamivudine- versus tenofovir-containing first-line combination antiretroviral treatment (cART) on HBV-related outcomes."7.79HIV-HBV coinfection in Southern Africa and the effect of lamivudine- versus tenofovir-containing cART on HBV outcomes. ( Botes, ME; Hamers, RL; Hoepelman, AI; Ive, P; Rinke de Wit, TF; Sigaloff, KC; Siwale, M; Stevens, WS; Wallis, CL; Zaaijer, HL, 2013)
"To evaluate the early virological response (EVR) to combined tenofovir-lamivudine or emtricitabine regimen in HBV/HIV-co-infected patients and the long-term efficacy of tenofovir."7.78Long-term outcome of primary non-responders to tenofovir therapy in HIV/HBV-co-infected patients: impact of HBV genotype G. ( Branger, M; Collin, G; Fraqueiro, G; Gervais, A; Hamet, G; Lada, O; Marcellin, P; Martinot-Peignoux, M; Matheron, S; Moucari, R; Peytavin, G; Roquebert, B, 2012)
"Among 141 HIV-HBV-coinfected patients treated with tenofovir in our centre, 87% were good-responders to therapy."7.78Quasispecies analysis and in vitro susceptibility of HBV strains isolated from HIV-HBV-coinfected patients with delayed response to tenofovir. ( Branger, M; Collin, G; Fraqueiro, G; Gervais, A; Lada, O; Leclerc, L; Marcellin, P; Martinot-Peignoux, M; Matheron, S; Moucari, R; Peytavin, G; Roquebert, B, 2012)
" His HBV is unresponsive to tenofovir/emtricitabine treatment demonstrated by persistent viremia despite lacking known resistance mutations and while having an undetectable HIV-1 viral load."7.77HIV-HBV vaccine escape mutant infection with loss of HBV surface antibody and persistent HBV viremia on tenofovir/emtricitabine without antiviral resistance. ( Holodniy, M; Schirmer, P; Winters, M, 2011)
"Liver steatosis was retrospectively evaluated in all consecutive biopsies performed in the period 2000-2008 in HCV mono-infected and HIV-HCV co-infected patients."5.39Absence of liver steatosis in HIV-HCV co-infected patients receiving regimens containing tenofovir or abacavir. ( Bisi, L; Borghi, V; Cossarizza, A; Manzini, L; Mussini, C, 2013)
"Coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (E/C/F/TAF) has high efficacy and improved renal and bone safety in multiple phase 3 trials; TAF single agent is being studied in 2 phase 3 trials in patients with chronic hepatitis B."5.22Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B-Coinfected Adults. ( Benson, P; Brinson, C; Brunetta, J; Cheng, A; Crofoot, G; Das, M; Fordyce, M; Gallant, J; Garner, W; McCallister, S; Mills, A; Oka, S, 2016)
" Using a computer-generated randomisation sequence, we randomly allocated antiretroviral-naive adult patients with HIV-1 and tuberculosis (aged ≥18 years with a plasma HIV RNA concentration of >1000 copies per mL) to receive raltegravir 400 mg twice a day, raltegravir 800 mg twice daily, or efavirenz 600 mg once daily plus tenofovir and lamivudine (1:1:1; stratified by country)."5.19Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial. ( Arnold, V; Barcellos, NT; Brites, C; Chêne, G; De Castro, N; Delaugerre, C; Fagard, C; Grinsztejn, B; Madruga, JV; Molina, JM; Morgado, M; Patey, O; Pilotto, JH; Santini-Oliveira, M; Santos, BR; Veloso, VG; Vorsatz, C, 2014)
"A 48-week PegIFN therapy was added to HBeAg positive-HIV co-infected patients on TDF and emtricitabine, or lamivudine for at least 6 months."5.19Role of a 48-week pegylated interferon therapy in hepatitis B e antigen positive HIV-co-infected patients on cART including tenofovir: EMVIPEG study. ( Barthe, Y; Bouix, C; Cacoub, P; Carrat, F; Lascoux-Combe, C; Lebossé, F; Maynard-Muet, M; Miailhes, P; Piroth, L; Pol, S; Rey, D; Sogni, P; Zoulim, F, 2014)
"The present report describes a case of a patient with hepatitis B virus (HBV)-human immunodeficiency virus (HIV) co-infection who was treated with tenofovir disoproxil (TDF)-based highly active antiretroviral therapy (HAART) and who achieved HBs antigen (Ag)/antibody (Ab) seroconversion."3.80An HBV-HIV co-infected patient treated with tenofovir-based therapy who achieved HBs antigen/antibody seroconversion. ( Abe, M; Hiasa, Y; Hirooka, M; Ikeda, Y; Koizumi, Y; Kumagi, T; Matsuura, B; Ochi, H; Tada, F; Takada, K; Tokumoto, Y; Watanabe, T, 2014)
" Treatment of chronic hepatitis C in patients coinfected with HIV is a complex problem associated with toxicities and drug interactions between HIV antiretrovirals and interferon and ribavirin."3.79Short communication: Interferon/ribavirin treatment for HCV is associated with the development of hypophosphatemia in HIV/hepatitis C virus-coinfected patients. ( Funk, EK; Heytens, L; Kohli, A; Kottilil, S; Kwan, R; Masur, H; Nelson, A; Polis, MA; Shaffer, A; Shivakumar, B; Sneller, M, 2013)
" We also found that co-infection with HCV and treatment by the antiretrovirat drug Tenofovir are significantly associated with the decline in renal function among our patients [p=0."3.79[Crucial risk factors for renal function deterioration of HIV-infected patients at the AIDS Clinic in Rambam Hospital]. ( Hassoun, G; Kedem, E; Mugrabi, F; Pollack, S; Shahar, E, 2013)
"This study assessed HIV-hepatitis B virus (HBV) coinfection in southern Africa in terms of prevalence, viral characteristics, occult HBV, and the effect of lamivudine- versus tenofovir-containing first-line combination antiretroviral treatment (cART) on HBV-related outcomes."3.79HIV-HBV coinfection in Southern Africa and the effect of lamivudine- versus tenofovir-containing cART on HBV outcomes. ( Botes, ME; Hamers, RL; Hoepelman, AI; Ive, P; Rinke de Wit, TF; Sigaloff, KC; Siwale, M; Stevens, WS; Wallis, CL; Zaaijer, HL, 2013)
"To evaluate the early virological response (EVR) to combined tenofovir-lamivudine or emtricitabine regimen in HBV/HIV-co-infected patients and the long-term efficacy of tenofovir."3.78Long-term outcome of primary non-responders to tenofovir therapy in HIV/HBV-co-infected patients: impact of HBV genotype G. ( Branger, M; Collin, G; Fraqueiro, G; Gervais, A; Hamet, G; Lada, O; Marcellin, P; Martinot-Peignoux, M; Matheron, S; Moucari, R; Peytavin, G; Roquebert, B, 2012)
"Among 141 HIV-HBV-coinfected patients treated with tenofovir in our centre, 87% were good-responders to therapy."3.78Quasispecies analysis and in vitro susceptibility of HBV strains isolated from HIV-HBV-coinfected patients with delayed response to tenofovir. ( Branger, M; Collin, G; Fraqueiro, G; Gervais, A; Lada, O; Leclerc, L; Marcellin, P; Martinot-Peignoux, M; Matheron, S; Moucari, R; Peytavin, G; Roquebert, B, 2012)
"Data on the efficacy of lamivudine (LAM)-, tenofovir (TDF)- and emtricitabine (FTC)-based antiretroviral therapy (HAART) in HBV-HIV coinfection are limited."3.78Five-year on-treatment efficacy of lamivudine-, tenofovir- and tenofovir + emtricitabine-based HAART in HBV-HIV-coinfected patients. ( Grabmeier-Pfistershammer, K; Kosi, L; Payer, BA; Peck-Radosavljevic, M; Reiberger, T; Rieger, A; Strassl, R, 2012)
" His HBV is unresponsive to tenofovir/emtricitabine treatment demonstrated by persistent viremia despite lacking known resistance mutations and while having an undetectable HIV-1 viral load."3.77HIV-HBV vaccine escape mutant infection with loss of HBV surface antibody and persistent HBV viremia on tenofovir/emtricitabine without antiviral resistance. ( Holodniy, M; Schirmer, P; Winters, M, 2011)
"The pharmacokinetic data support coadministration of daclatasvir with atazanavir/ritonavir, efavirenz and/or tenofovir."2.78Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir. ( Bertz, R; Bifano, M; Grasela, D; Hartstra, J; Hwang, C; Kandoussi, H; Oosterhuis, B; Sevinsky, H; Tiessen, R; Velinova-Donga, M, 2013)
"Several drugs are available to treat hepatitis B."2.49Suppression of HBV by tenofovir in HBV/HIV coinfected patients: a systematic review and meta-analysis. ( Bani-Sadr, F; de Vries-Sluijs, T; Dunn, D; Gilson, R; Jain, MK; Kuzushita, N; Mauss, S; Nüesch, R; Núñez, M; Peters, M; Pillay, D; Price, H; Reiberger, T; Stephan, C; Tan, L, 2013)
"Specialized treatment of CHB in pregnancy, coinfection, decompensated cirrhosis, and posttransplant is safe and effective."2.48New advances in chronic hepatitis B. ( Lee, WM; Tujios, SR, 2012)
"Those at risk for liver disease progression are usually treated with a combination of interferon (IFN) and ribavirin (RBV), which is not highly effective; it has low rates of sustained virologic response (SVR), especially for coinfected patients with HCV genotype 1 and those of African descent."2.48Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals. ( Naggie, S; Sulkowski, MS, 2012)
"In areas where chronic hepatitis B virus infection is prevalent, acute hepatitis E virus superinfection on chronic hepatitis B virus infection occurs sporadically."1.48Seroclearance of hepatitis B surface antigen following hepatitis E exacerbation on chronic hepatitis E and B dual infection in a renal transplant recipient: a case report. ( Chiang, YJ; Chu, YD; Yeh, CS; Yeh, CT, 2018)
"Fanconi syndrome is a rare adverse effect of tenofovir disoproxil fumarate (TDF)."1.46Short Communication: Resolution of Tenofovir Disoproxil Fumarate Induced Fanconi Syndrome with Switch to Tenofovir Alafenamide Fumarate in a HIV-1 and Hepatitis B Coinfected Patient. ( Karris, MY, 2017)
"Dolutegravir (DTG) has been studied in three trials in HIV treatment-naive participants, showing noninferiority compared with raltegravir (RAL), and superiority compared with efavirenz and ritonavir-boosted darunavir."1.42Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials. ( Almond, S; Arasteh, K; Brennan, C; Brinson, C; Cuffe, RL; Eron, J; Górgolas, M; Granier, C; Nichols, WG; Pappa, K; Rachlis, A; Raffi, F; Walmsley, S, 2015)
"Telbivudine seemed to be a candidate for exclusive anti-HBV therapy because it exerts no significant in vitro activity against HIV."1.39In vivo antiviral activity of telbivudine against HIV-1: a case report. ( Bonadies, G; Borgia, G; Borrelli, F; Buonomo, AR; Carleo, MA; Gentile, I; Portella, G, 2013)
"Liver steatosis was retrospectively evaluated in all consecutive biopsies performed in the period 2000-2008 in HCV mono-infected and HIV-HCV co-infected patients."1.39Absence of liver steatosis in HIV-HCV co-infected patients receiving regimens containing tenofovir or abacavir. ( Bisi, L; Borghi, V; Cossarizza, A; Manzini, L; Mussini, C, 2013)
"TDF/emtricitabine was less likely to be associated with detectable HBV than other regimens, including TDF monotherapy (odds ratio, 2."1.39Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus. ( Avihingsanon, A; Bowden, S; Dore, GJ; Finlayson, R; Hoy, JF; Lewin, SR; Littlejohn, M; Locarnini, S; Matthews, GV; Revill, PA; Ruxrungtham, K; Sasadeusz, J; Saulynas, M; Seaberg, EC; Thio, CL, 2013)

Research

Studies (52)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's50 (96.15)24.3611
2020's2 (3.85)2.80

Authors

AuthorsStudies
Sarowar, A1
Coffin, CS2
Fung, S1
Wong, A1
Doucette, K1
Truong, D1
Conway, B1
Haylock-Jacobs, S1
Ramji, A1
Hansen, BE2
Janssen, HLA1
Cooper, C1
Huhn, GD1
Ramgopal, M1
Jain, MK2
Hinestrosa, F1
Asmuth, DM1
Slim, J1
Goldstein, D1
Applin, S1
Ryu, JH1
Jiang, S1
Cox, S1
Das, M2
Nguyen-Cleary, T1
Piontkowsky, D1
Guyer, B1
Rossaro, L1
Haubrich, RH1
Karris, MY1
Tartaglia, A1
Ferrara, SM1
Sica, S1
Santantonio, T1
Yeh, CT1
Yeh, CS1
Chu, YD1
Chiang, YJ1
MacBrayne, CE1
Marks, KM1
Fierer, DS1
Naggie, S2
Chung, RT1
Hughes, MD1
Kim, AY1
Peters, MG1
Brainard, DM1
Seifert, SM1
Castillo-Mancilla, JR1
Bushman, LR1
Anderson, PL1
Kiser, JJ1
Naing, C1
Poovorawan, Y1
Tong, KS1
Tsai, WC1
Hsu, WT1
Liu, WD1
Sun, HY1
Chuang, YC1
Huang, YS1
Cheng, A2
Lin, KY1
Huang, YC1
Chen, GJ1
Huang, SH1
Sheng, WH1
Hsieh, SM1
Hung, CC1
Chang, SC1
Childs, K1
Joshi, D1
Byrne, R1
Bruce, M1
Carey, I1
Agarwal, K1
Taylor, C1
Antonucci, G1
Mazzotta, F1
Angeletti, C1
Girardi, E1
Puoti, M1
De Stefano, G1
Grossi, P1
Petrosillo, N1
Pagano, G1
Cassola, G1
Orani, A1
Sagnelli, C2
Armignacco, O1
Sagnelli, E2
Funk, EK1
Shaffer, A1
Shivakumar, B1
Sneller, M1
Polis, MA1
Masur, H1
Heytens, L1
Nelson, A1
Kwan, R1
Kottilil, S1
Kohli, A1
Núñez, M2
Mendes-Correa, MC1
Shahar, E1
Mugrabi, F1
Kedem, E1
Hassoun, G1
Pollack, S1
Price, H1
Dunn, D1
Pillay, D1
Bani-Sadr, F1
de Vries-Sluijs, T1
Kuzushita, N1
Mauss, S1
Nüesch, R1
Peters, M1
Reiberger, T2
Stephan, C1
Tan, L1
Gilson, R1
Hamers, RL1
Zaaijer, HL2
Wallis, CL1
Siwale, M1
Ive, P1
Botes, ME1
Sigaloff, KC1
Hoepelman, AI1
Stevens, WS1
Rinke de Wit, TF1
Soriano, V1
Poveda, E1
Vispo, E1
Barreiro, P1
Pradat, P1
Le Pogam, MA1
Okon, JB1
Trolliet, P1
Miailhes, P2
Brochier, C1
Maynard, M1
Bailly, F1
Zoulim, F5
Cotte, L1
Bifano, M1
Hwang, C1
Oosterhuis, B1
Hartstra, J1
Grasela, D1
Tiessen, R1
Velinova-Donga, M1
Kandoussi, H1
Sevinsky, H1
Bertz, R1
Gentile, I1
Bonadies, G1
Carleo, MA1
Buonomo, AR1
Borrelli, F1
Portella, G1
Borgia, G1
Hafkin, JS1
Osborn, MK1
Localio, AR1
Amorosa, VK1
Kostman, JR1
Stern, JJ1
De La Torre, P1
Mounzer, K1
Frank, I1
Gross, R1
Chang, KM1
Lo Re, V1
Boyd, A4
Maylin, S4
Gozlan, J2
Delaugerre, C5
Simon, F3
Girard, PM4
Lacombe, K4
Kang, M1
Hollabaugh, K1
Pham, V1
Koletar, SL1
Wu, K1
Smurzynski, M1
Aberg, JA1
Grinsztejn, B1
De Castro, N1
Arnold, V1
Veloso, VG1
Morgado, M1
Pilotto, JH1
Brites, C1
Madruga, JV1
Barcellos, NT1
Santos, BR1
Vorsatz, C1
Fagard, C1
Santini-Oliveira, M1
Patey, O1
Chêne, G1
Molina, JM1
Peytavin, G3
Pisaturo, M1
Martini, S1
Filippini, P1
Coppola, N1
Maynard-Muet, M1
Lebossé, F1
Carrat, F1
Bouix, C1
Lascoux-Combe, C1
Sogni, P1
Rey, D1
Barthe, Y1
Pol, S1
Cacoub, P1
Piroth, L1
Watanabe, T1
Tokumoto, Y1
Hirooka, M1
Koizumi, Y1
Tada, F1
Ochi, H1
Abe, M1
Kumagi, T1
Ikeda, Y1
Matsuura, B1
Takada, K1
Hiasa, Y1
Gürtler, LG1
Sabo, JP1
Kort, J1
Ballow, C1
Haschke, M1
Battegay, M1
Fuhr, R1
Girlich, B1
Schobelock, M1
Feifel, U1
Lang, B1
Li, Y1
Elgadi, M1
Mweemba, A1
Zanolini, A1
Mulenga, L1
Emge, D1
Chi, BH1
Wandeler, G1
Vinikoor, MJ1
James, G1
Sidhu, P1
Raza, M1
Raffi, F1
Rachlis, A1
Brinson, C2
Arasteh, K1
Górgolas, M1
Brennan, C1
Pappa, K1
Almond, S1
Granier, C1
Nichols, WG1
Cuffe, RL1
Eron, J1
Walmsley, S1
Marszalek, RM1
Bae-Harboe, YS1
Mahalingam, M1
Masterpol, K1
Garcia, M1
Le Moal, G1
Godet, C1
Beraud, G1
Chagneau-Derrode, C1
Roblot, F1
Gallant, J1
Brunetta, J1
Crofoot, G1
Benson, P1
Mills, A1
Oka, S1
Garner, W1
Fordyce, M1
McCallister, S1
Cholongitas, E1
Goulis, I1
Antoniadis, N1
Fouzas, I1
Imvrios, G1
Giakoustidis, D1
Giouleme, O1
Papanikolaou, V1
Akriviadis, E1
Vasiliadis, T1
Schirmer, P1
Winters, M1
Holodniy, M1
Lada, O2
Gervais, A2
Branger, M2
Roquebert, B2
Collin, G2
Fraqueiro, G2
Moucari, R2
Hamet, G1
Martinot-Peignoux, M3
Matheron, S2
Marcellin, P3
Lavocat, F2
Leclerc, L1
Tujios, SR1
Lee, WM1
Sulkowski, MS1
Tuaillon, E1
Lozano, C1
Kuster, N1
Poinso, A1
Kania, D1
Nagot, N1
Mondain, AM1
Pageaux, GP1
Ducos, J1
Van de Perre, P1
Reynes, J1
Zoutendijk, R1
de Vries-Sluijs, TE1
Reijnders, JG1
Mulder, JW1
Kroon, FP1
Richter, C1
van der Eijk, AA1
Sonneveld, MJ1
de Man, RA1
van der Ende, ME1
Janssen, HL1
Kim, JH1
Psevdos, G1
Sharp, V1
Mikulska, M1
Taramasso, L1
Giacobbe, DR1
Caligiuri, P1
Bruzzone, B1
Di Biagio, A1
Viscoli, C1
Naranbhai, V1
Abdool Karim, SS1
Altfeld, M1
Samsunder, N1
Durgiah, R1
Sibeko, S1
Abdool Karim, Q1
Carr, WH1
Kosi, L1
Payer, BA1
Grabmeier-Pfistershammer, K1
Strassl, R1
Rieger, A1
Peck-Radosavljevic, M1
Borghi, V1
Bisi, L1
Manzini, L1
Cossarizza, A1
Mussini, C1
Fung, SK1
Ma, MM1
Matthews, GV1
Seaberg, EC1
Avihingsanon, A1
Bowden, S1
Dore, GJ1
Lewin, SR1
Sasadeusz, J1
Revill, PA1
Littlejohn, M1
Hoy, JF1
Finlayson, R1
Ruxrungtham, K1
Saulynas, M1
Locarnini, S1
Thio, CL1
Bagnard, G1
Lapalus, M1

Clinical Trials (5)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase 3b Randomized, Open-label, Controlled Study of the Efficacy, Safety and Tolerability of 12 Weeks of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Subjects Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamid[NCT02707601]Phase 3150 participants (Actual)Interventional2016-04-01Completed
Liver Fibrosis in Zambian HIV-HBV Co-infected Patients: a Long-term Prospective Cohort Study[NCT02344680]303 participants (Actual)Observational2015-10-31Active, not recruiting
Phase II Open-label Randomized Multicenter Trial to Compare the Efficacy and Safety of Two Different Doses of Raltegravir and Efavirenz, All in Combination With Tenofovir and Lamivudine, in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuber[NCT00822315]Phase 2155 participants (Actual)Interventional2009-07-31Completed
Multi-center Study Evaluating Persistence of Hepatitis B Virus Replication, Long-term Prognostic Indicators and Their Clinical Relevance in Patients Co-infected With the Human Immunodeficiency Virus and Chronic Hepatitis B[NCT02889094]152 participants (Actual)Observational2016-10-31Active, not recruiting
Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (Genvoya) as Maintenance Treatment of HIV-1/Hepatitis B Virus (HBV)-Coinfected Patients: an Observational Study[NCT03425994]275 participants (Actual)Observational [Patient Registry]2018-02-06Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Percentage of Participants Experiencing Grades 1 Through 4 Adverse Events After Switch to E/C/F/TAF or F/R/TAF Throughout the Study and During Coadministeration With LDV/SOF Treatment

(NCT02707601)
Timeframe: Up to 32 weeks plus 30 days

Interventionpercentage of participants (Number)
E/C/F/TAF + LDV/SOF (Co-administration: Week 8 to Week 20)62.5
F/R/TAF + LDV/SOF (Co-administration: Week 8 to Week 20)69.4
E/C/F/TAF + LDV/SOF (Whole Study: Day 1 to Post-HCV Week 12)83.8
F/R/TAF + LDV/SOF (Whole Study: Day 1 to Post-HCV to Week 12)79.7

Percentage of Participants With HCV RNA < LLOQ at 12 Weeks After Discontinuation of LDV/SOF Treatment (SVR12)

Sustained Virologic Response (SVR12) was defined as HCV RNA < the lower limit of quantitation (LLOQ) at 12 weeks after stopping LDV/SOF treatment. (NCT02707601)
Timeframe: HCV Posttreatment Week 12

Interventionpercentage of participants (Number)
E/C/F/TAF + LDV/SOF98.6
F/R/TAF + LDV/SOF95.8

Percentage of Participants With HCV RNA < LLOQ at 4 Weeks After Discontinuation of LDV/SOF Treatment (SVR4)

SVR4 was defined as HCV RNA < LLOQ at 4 weeks after stopping LDV/SOF treatment. (NCT02707601)
Timeframe: HCV Posttreatment Week 4

Interventionpercentage of participants (Number)
E/C/F/TAF + LDV/SOF98.6
F/R/TAF + LDV/SOF98.6

Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL (Virologic Failure) 24 Weeks After Start of the F/TAF-Based Regimen Using Modified FDA Snapshot Algorithm

The percentage of participants with HIV-1 RNA ≥ 50 copies/mL 24 weeks after start of the F/TAF-based regimen were analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT02707601)
Timeframe: 24 weeks after start of HIV treatment

Interventionpercentage of participants (Number)
E/C/F/TAF + LDV/SOF1.4
F/R/TAF + LDV/SOF1.4

Reviews

7 reviews available for adenine and Co-infection

ArticleYear
Comparative effectiveness of anti-viral drugs with dual activity for treating hepatitis B and HIV co-infected patients: a network meta-analysis.
    BMC infectious diseases, 2018, Nov-14, Volume: 18, Issue:1

    Topics: Adenine; Adult; Aged; Antiviral Agents; Coinfection; Emtricitabine; Female; Hepatitis B; Hepatitis B

2018
Viral hepatitis and HIV: update and management.
    Antiviral therapy, 2013, Volume: 18, Issue:3 Pt B

    Topics: Adenine; Antiretroviral Therapy, Highly Active; Antiviral Agents; Coinfection; Drug Therapy, Combina

2013
Suppression of HBV by tenofovir in HBV/HIV coinfected patients: a systematic review and meta-analysis.
    PloS one, 2013, Volume: 8, Issue:7

    Topics: Adenine; Anti-HIV Agents; Coinfection; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Organ

2013
Hepatitis B in HIV-infected patients.
    Clinics in liver disease, 2013, Volume: 17, Issue:3

    Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Coinfection; Drug Resistance, Viral; Hepatitis B Vaccine

2013
Advances in the treatment of hepatitis B virus/hepatitis C virus coinfection.
    Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:10

    Topics: Adenine; Antiviral Agents; Coinfection; DNA, Viral; Drug Therapy, Combination; Guanine; Hepacivirus;

2014
New advances in chronic hepatitis B.
    Current opinion in gastroenterology, 2012, Volume: 28, Issue:3

    Topics: Adenine; Antiviral Agents; Coinfection; Disease Progression; Drug Resistance, Viral; Female; Guanine

2012
Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals.
    Gastroenterology, 2012, Volume: 142, Issue:6

    Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Coinfection; Deoxycytidine; Dideoxynucleosides; Disease

2012

Trials

8 trials available for adenine and Co-infection

ArticleYear
HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens.
    PloS one, 2020, Volume: 15, Issue:1

    Topics: Adenine; Adult; Aged; Alanine; Benzimidazoles; Coinfection; Drug Combinations; Drug Resistance, Vira

2020
Effects of sofosbuvir-based hepatitis C treatment on the pharmacokinetics of tenofovir in HIV/HCV-coinfected individuals receiving tenofovir disoproxil fumarate.
    The Journal of antimicrobial chemotherapy, 2018, 08-01, Volume: 73, Issue:8

    Topics: Adenine; Adult; Antiviral Agents; Benzimidazoles; Coinfection; Drug Interactions; Fluorenes; Hepatit

2018
Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir.
    Antiviral therapy, 2013, Volume: 18, Issue:7

    Topics: Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Carbamates;

2013
Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial.
    The Lancet. Infectious diseases, 2014, Volume: 14, Issue:6

    Topics: Adenine; Adult; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Antitubercular Agen

2014
Persistent viremia in human immunodeficiency virus/hepatitis B coinfected patients undergoing long-term tenofovir: virological and clinical implications.
    Hepatology (Baltimore, Md.), 2014, Volume: 60, Issue:2

    Topics: Adenine; Adult; Coinfection; DNA, Viral; Drug Resistance, Viral; Female; Follow-Up Studies; Genotype

2014
Role of a 48-week pegylated interferon therapy in hepatitis B e antigen positive HIV-co-infected patients on cART including tenofovir: EMVIPEG study.
    Journal of hepatology, 2014, Volume: 61, Issue:4

    Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; Coinf

2014
Clinical assessment of potential drug interactions of faldaprevir, a hepatitis C virus protease inhibitor, with darunavir/ritonavir, efavirenz, and tenofovir.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2014, Nov-15, Volume: 59, Issue:10

    Topics: Adenine; Adult; Alkynes; Aminoisobutyric Acids; Anti-HIV Agents; Antiretroviral Therapy, Highly Acti

2014
Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B-Coinfected Adults.
    Journal of acquired immune deficiency syndromes (1999), 2016, 11-01, Volume: 73, Issue:3

    Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Coinfection; Drug Combinations; Drug Substitution; Em

2016

Other Studies

37 other studies available for adenine and Co-infection

ArticleYear
Brief Report: Effect of Antiretroviral Switch From Tenofovir Disoproxil fumarate to Tenofovir Alafenamide on Alanine Aminotransferase, Lipid Profiles, and Renal Function in HIV/HBV-Coinfected Individuals in a Nationwide Canadian Study.
    Journal of acquired immune deficiency syndromes (1999), 2022, 12-01, Volume: 91, Issue:4

    Topics: Adenine; Alanine; Alanine Transaminase; Anti-Retroviral Agents; Canada; Cholesterol; Coinfection; He

2022
Short Communication: Resolution of Tenofovir Disoproxil Fumarate Induced Fanconi Syndrome with Switch to Tenofovir Alafenamide Fumarate in a HIV-1 and Hepatitis B Coinfected Patient.
    AIDS research and human retroviruses, 2017, Volume: 33, Issue:7

    Topics: Adenine; Alanine; Anti-HIV Agents; Coinfection; Fanconi Syndrome; Hepatitis B, Chronic; HIV Infectio

2017
Successful treatment with tenofovir alafenamide of a HIV/hepatitis B virus coinfected patient with HIV and hepatitis B virus drug resistance, end-stage renal disease on haemodialysis.
    AIDS (London, England), 2017, 10-23, Volume: 31, Issue:16

    Topics: Adenine; Adult; Alanine; Antiviral Agents; Coinfection; Drug Resistance, Viral; Female; Hepatitis B,

2017
Seroclearance of hepatitis B surface antigen following hepatitis E exacerbation on chronic hepatitis E and B dual infection in a renal transplant recipient: a case report.
    Journal of medical case reports, 2018, Feb-28, Volume: 12, Issue:1

    Topics: Adenine; Coinfection; Disease Progression; DNA, Viral; Female; Graft Rejection; Hepatitis B Surface

2018
Impact of antiretroviral therapy containing tenofovir disoproxil fumarate on the survival of patients with HBV and HIV coinfection.
    Liver international : official journal of the International Association for the Study of the Liver, 2019, Volume: 39, Issue:8

    Topics: Adenine; Adult; Anti-Retroviral Agents; Coinfection; Female; Hepatitis B; HIV Infections; Humans; Ma

2019
Tenofovir-based combination therapy for HIV/HBV co-infection: factors associated with a partial HBV virological response in patients with undetectable HIV viraemia.
    AIDS (London, England), 2013, Jun-01, Volume: 27, Issue:9

    Topics: Adenine; Adult; Anti-HIV Agents; Case-Control Studies; Coinfection; Deoxycytidine; DNA, Viral; Drug

2013
Access to treatment for HBV infection and its consistency with 2008 European guidelines in a multicentre cross-sectional study of HIV/HBV co-infected patients in Italy.
    BMC research notes, 2013, Apr-17, Volume: 6

    Topics: Adenine; Adult; Anti-Retroviral Agents; Coinfection; Cross-Sectional Studies; Deoxycytidine; Emtrici

2013
Short communication: Interferon/ribavirin treatment for HCV is associated with the development of hypophosphatemia in HIV/hepatitis C virus-coinfected patients.
    AIDS research and human retroviruses, 2013, Volume: 29, Issue:9

    Topics: Adenine; Adult; Anti-HIV Agents; Antiviral Agents; Coinfection; Drug Interactions; Drug Therapy, Com

2013
[Crucial risk factors for renal function deterioration of HIV-infected patients at the AIDS Clinic in Rambam Hospital].
    Harefuah, 2013, Volume: 152, Issue:4

    Topics: Adenine; Adult; Aged; Anti-HIV Agents; Coinfection; Female; Glomerular Filtration Rate; Hepatitis C;

2013
HIV-HBV coinfection in Southern Africa and the effect of lamivudine- versus tenofovir-containing cART on HBV outcomes.
    Journal of acquired immune deficiency syndromes (1999), 2013, Oct-01, Volume: 64, Issue:2

    Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Coinfection;

2013
Evolution of glomerular filtration rate in HIV-infected, HIV-HBV-coinfected and HBV-infected patients receiving tenofovir disoproxil fumarate.
    Journal of viral hepatitis, 2013, Volume: 20, Issue:9

    Topics: Adenine; Adult; Antiviral Agents; Coinfection; Female; Glomerular Filtration Rate; Hepatitis B, Chro

2013
In vivo antiviral activity of telbivudine against HIV-1: a case report.
    Le infezioni in medicina, 2013, Volume: 21, Issue:3

    Topics: Acute Disease; Adenine; Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Hepatitis B

2013
Incidence and risk factors for incomplete HBV DNA suppression in HIV/HBV-co-infected patients initiating tenofovir-based therapy.
    Journal of viral hepatitis, 2014, Volume: 21, Issue:4

    Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Coinfection;

2014
Use of hepatitis B surface and "e" antigen quantification during extensive treatment with tenofovir in patients co-infected with HIV-HBV.
    Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35, Issue:3

    Topics: Adenine; Adult; Anti-HIV Agents; Coinfection; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis

2015
Virologic and serologic outcomes of mono versus dual HBV therapy and characterization of HIV/HBV coinfection in a US cohort.
    Journal of acquired immune deficiency syndromes (1999), 2014, Jun-01, Volume: 66, Issue:2

    Topics: Adenine; Adult; Antibodies, Viral; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymp

2014
An HBV-HIV co-infected patient treated with tenofovir-based therapy who achieved HBs antigen/antibody seroconversion.
    Internal medicine (Tokyo, Japan), 2014, Volume: 53, Issue:12

    Topics: Adenine; Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Coinfection; Hepatitis

2014
Effect of antiretroviral HIV therapy on hepatitis B virus replication and pathogenicity.
    Intervirology, 2014, Volume: 57, Issue:3-4

    Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Coinfection; Deoxycytidine; Emtrici

2014
Chronic hepatitis B virus coinfection is associated with renal impairment among Zambian HIV-infected adults.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2014, Dec-15, Volume: 59, Issue:12

    Topics: Adenine; Adolescent; Adult; Africa; Anti-HIV Agents; Coinfection; Female; Glomerular Filtration Rate

2014
First report of successful clearance of hepatitis B and D coinfection with tenofovir monotherapy.
    Hepatology (Baltimore, Md.), 2015, Volume: 62, Issue:1

    Topics: Adenine; Adult; Coinfection; Hepatitis B; Hepatitis D; Humans; Male; Organophosphonates; Reverse Tra

2015
Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials.
    AIDS (London, England), 2015, Jan-14, Volume: 29, Issue:2

    Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Clinic

2015
Painless penile papule.
    The Journal of family practice, 2015, Volume: 64, Issue:3

    Topics: Adenine; Adult; Anti-Bacterial Agents; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biops

2015
First case report of renal improvement on tenofovir alafenamide in an HIV/hepatitis B virus-coinfected patient with adefovir-induced Fanconi's syndrome.
    AIDS (London, England), 2016, 06-01, Volume: 30, Issue:9

    Topics: Absorptiometry, Photon; Adenine; Alanine; Coinfection; Dose-Response Relationship, Drug; Fanconi Syn

2016
Nucleos(t)ide analog(s) prophylaxis after hepatitis B immunoglobulin withdrawal against hepatitis B and D recurrence after liver transplantation.
    Transplant infectious disease : an official journal of the Transplantation Society, 2016, Volume: 18, Issue:5

    Topics: Adenine; Adult; Antiviral Agents; Coinfection; DNA, Viral; Drug Therapy, Combination; Female; Guanin

2016
HIV-HBV vaccine escape mutant infection with loss of HBV surface antibody and persistent HBV viremia on tenofovir/emtricitabine without antiviral resistance.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2011, Volume: 52, Issue:3

    Topics: Adenine; Antiviral Agents; Coinfection; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Hepati

2011
Long-term outcome of primary non-responders to tenofovir therapy in HIV/HBV-co-infected patients: impact of HBV genotype G.
    Liver international : official journal of the International Association for the Study of the Liver, 2012, Volume: 32, Issue:1

    Topics: Adenine; Adult; Anti-HIV Agents; Coinfection; Deoxycytidine; DNA Mutational Analysis; DNA, Viral; Dr

2012
Comparison between Elecsys HBsAg II and architect HBsAg QT assays for quantification of hepatitis B surface antigen among patients coinfected with HIV and hepatitis B virus.
    Clinical and vaccine immunology : CVI, 2012, Volume: 19, Issue:2

    Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Coinfection; Female; Genotype; Hepatitis B; H

2012
Quasispecies analysis and in vitro susceptibility of HBV strains isolated from HIV-HBV-coinfected patients with delayed response to tenofovir.
    Antiviral therapy, 2012, Volume: 17, Issue:1

    Topics: Adenine; Adult; Antiviral Agents; Cloning, Molecular; Coinfection; DNA, Viral; Drug Resistance, Vira

2012
Long-term hepatitis B virus surface antigen decay in HIV-1/hepatitis B virus-coinfected adults initiating a tenofovir-containing regimen.
    Journal of clinical microbiology, 2012, Volume: 50, Issue:9

    Topics: Adenine; Adult; Anti-HIV Agents; Coinfection; Hepatitis B Surface Antigens; Hepatitis B, Chronic; HI

2012
Hepatitis B surface antigen declines and clearance during long-term tenofovir therapy in patients coinfected with HBV and HIV.
    The Journal of infectious diseases, 2012, Sep-15, Volume: 206, Issue:6

    Topics: Adenine; Adult; Antiviral Agents; CD4 Lymphocyte Count; Cohort Studies; Coinfection; Drug Administra

2012
Five-year review of HIV-hepatitis B virus (HBV) co-infected patients in a New York City AIDS center.
    Journal of Korean medical science, 2012, Volume: 27, Issue:7

    Topics: Adenine; Adult; Anti-HIV Agents; Coinfection; Female; Hepatitis B; Hepatitis B e Antigens; HIV Infec

2012
Case report: management and HBV sequencing in a patient co-infected with HBV and HIV failing tenofovir.
    Journal of medical virology, 2012, Volume: 84, Issue:9

    Topics: Adenine; Anti-HIV Agents; Coinfection; Drug Resistance, Viral; Gene Products, pol; Hepatitis B virus

2012
Innate immune activation enhances hiv acquisition in women, diminishing the effectiveness of tenofovir microbicide gel.
    The Journal of infectious diseases, 2012, Oct-01, Volume: 206, Issue:7

    Topics: Adenine; Adult; Anti-HIV Agents; Avian Proteins; Case-Control Studies; Coinfection; Cytokines; Disea

2012
Five-year on-treatment efficacy of lamivudine-, tenofovir- and tenofovir + emtricitabine-based HAART in HBV-HIV-coinfected patients.
    Journal of viral hepatitis, 2012, Volume: 19, Issue:11

    Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Coinfection; Deoxycytid

2012
Absence of liver steatosis in HIV-HCV co-infected patients receiving regimens containing tenofovir or abacavir.
    Infection, 2013, Volume: 41, Issue:2

    Topics: Adenine; Adult; Anti-HIV Agents; Coinfection; Dideoxynucleosides; Fatty Liver; Female; Genotype; Hep

2013
Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines.
    Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2012, Volume: 26, Issue:12

    Topics: Adenine; Allied Health Personnel; Antibodies, Viral; Antiviral Agents; Canada; Coinfection; Drug Res

2012
Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2013, Volume: 56, Issue:9

    Topics: Adenine; Adult; Aged; Antiretroviral Therapy, Highly Active; Antiviral Agents; Australia; Coinfectio

2013
Quantification of hepatitis B e antigen between Elecsys HBeAg and Architect HBeAg assays among patients infected with hepatitis B virus.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2013, Volume: 56, Issue:4

    Topics: Adenine; Adult; CD4 Lymphocyte Count; Cohort Studies; Coinfection; Female; Genotype; Hepatitis B e A

2013